Market Overview

Lowe's Reports Q2 Earnings Beat

Lowe's Reports Q2 Earnings Beat

Lowe's Companies, Inc. (NYSE: LOW) reported second-quarter earnings of $2.15 per share, which beat the analyst consensus estimate of $2.01.

The company reported sales for the second-quarter increased 0.5% to $21.0 billion from $20.9 billion in the second-quarter of 2018, and comparable sales increased 2.3%.
Lowe's reported net earnings of $1.7 billion and diluted earnings per share of $2.14 for the quarter ended Aug. 2, 2019, compared to net earnings of $1.5 billion and diluted earnings per share of $1.86 in the second-quarter of 2018.

The company sees fiscal year 2019 guidance adjusted EPS $5.45-$5.65 versus the $5.57 estimate.

"We capitalized on spring demand, strong holiday event execution and growth in Paint and our Pro business to deliver strong second-quarter results. Despite lumber deflation and difficult weather, we are pleased that we delivered positive comparable sales in all 15 geographic regions of the U.S. This is a reflection of a solid macroeconomic backdrop and continued momentum executing our retail fundamentals framework," said Marvin Ellison, Lowe's CEO in a statement.

Lowe's shares were trading up 11.88% at $109.50 in Wednesday’s pre-market session. The stock has a 52-week high of $118.23 and a 52-week low of $84.75.

Related Links:

Home Depot Trades Higher On Q2 Earnings Beat

This Analyst Prefers Lowe's Over Home Depot Ahead Of Earnings

Posted-In: Earnings News Best of Benzinga


Related Articles (LOW)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Target Reports Q2 Earnings Beat, Raises Guidance